Holen Sie sich die Stockscreener-App
85.56
2.75%
2.29
Schlusskurs vom Vortag:
$83.27
Offen:
$83.27
24-Stunden-Volumen:
563.28K
Relative Volume:
0.95
Marktkapitalisierung:
$5.56B
Einnahmen:
$569.61M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-6.2892
EPS:
-13.6043
Netto-Cashflow:
$54.87M
1W Leistung:
+0.58%
1M Leistung:
-4.62%
6M Leistung:
-7.48%
1J Leistung:
+19.53%
1-Tages-Spanne:
$82.17
$85.62
1-Wochen-Bereich:
$80.24
$85.62
52-Wochen-Spanne:
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
85.56 | 5.56B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-02 | Eingeleitet | Citigroup | Buy |
| 2026-05-19 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Form 4 Mirum Pharmaceuticals Inc: Robert Paul Myers (Chief Medical Officer) For: 9 October - Investing.com Nigeria
Form 4 Mirum Pharmaceuticals Inc: Robert Paul Myers (Chief Medical Officer) For: 9 October By Investing.com - Investing.com South Africa
Medical chief receives 40,000 options and a 25,000-share stock grant at Mirum Pharmaceuticals (MIRM). - Stock Titan
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Zacks Investment Research
Form 4 Mirum Pharmaceuticals Inc For: 11 October By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals, Inc.common stock (Nasdaq:MIRM) Stock Quote - FinancialContent
Form 4 Mirum Pharmaceuticals Inc For: 6 October By Investing.com - Investing.com Nigeria
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - stocktitan.net
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - stocktitan.net
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com UK
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - Investing.com
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Canada
Mirum CEO Christopher Peetz sells $2.96 million in shares By Investing.com - Investing.com Nigeria
Mirum CEO Christopher Peetz sells $2.96 million in shares - Investing.com
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - stocktitan.net
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - stocktitan.net
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - stocktitan.net
Five investor conferences are on Mirum’s September schedule - Stock Titan
Mirum (NASDAQ: MIRM) investor plans Sept. stock sale after 40,000 shares sold - Stock Titan
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc (08D) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc. (MIRM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mirum Pharmaceuticals Inc-Aktie (MIRM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Oct 06 '26 |
Option Exercise |
17.31 |
12,197 |
211,179 |
206,637 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Sep 14 '26 |
Sale |
98.37 |
9,943 |
978,093 |
44,745 |
| ERIC BJERKHOLT | Officer |
Sep 14 '26 |
Proposed Sale |
98.37 |
9,943 |
978,093 |
0 |
| JOLANDA MARIE HOWE | Officer |
Sep 02 '26 |
Proposed Sale |
100.00 |
658 |
65,800 |
0 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Sep 02 '26 |
Sale |
100.00 |
658 |
65,800 |
616 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Sep 01 '26 |
Sale |
98.68 |
30,000 |
2,960,401 |
194,440 |
| CHRISTOPHER PEETZ | Officer |
Sep 01 '26 |
Proposed Sale |
98.68 |
30,000 |
2,960,319 |
0 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Sep 01 '26 |
Option Exercise |
2.94 |
30,000 |
88,080 |
224,440 |
| JOLANDA MARIE HOWE | Officer |
Aug 18 '26 |
Proposed Sale |
100.00 |
40,000 |
4,000,000 |
0 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Aug 18 '26 |
Sale |
100.00 |
40,000 |
4,000,000 |
1,274 |
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):